Supplement manufacturers and suppliers in China sought return to normalcy as they resumed operations after the extended Chinese New Year holiday – lengthened by the COVID-19 outbreak – came to an end.
Examples included Lonza which resumed production of its L-carnitine at Guangdong a few days ago on Feb 10, while DSM said its large-scale sites had been fully operational.
For Lonza, its L-carnitine production site at Nansha, Guangdong resumed operation only this week. The epidemic had required the company to await approval from the authorities to recommence operation.
Its other site for producing nutrition capsule at Suzhou had earlier resumed operation on Jan 30, head of global marketing communications, Lonza Nutritional Ingredients, Aparna Parikh, said in response to queries from NutraIngredients-Asia.